Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137771 · ClinicalTrials.gov registry record · Phase 2
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
A Phase 2 study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-Small Cell Lung Carcinoma, sponsored by NRG Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT03137771 is a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-Small Cell Lung Carcinoma that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 218 participants, below the 680-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03137771, a Phase 2 study of Stage IV Non-small Cell Lung Cancer and Recurrent Non-Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by NRG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- RADIATION Intensity-Modulated Radiation Therapy (IMRT)
- RADIATION 3-Dimensional Conformal Radiation Therapy (3D-CRT)
- DRUG Pemetrexed Disodium
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- City of Hope Comprehensive Cancer Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Memorial Medical Center - Modesto
- Saint Joseph Hospital - Orange - Orange
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Sutter Medical Center Sacramento - Sacramento
- University of California Davis Comprehensive Cancer Center - Sacramento
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Mayo Clinic Hospital in Arizona - Phoenix
- Arizona Center for Cancer Care - Scottsdale - Scottsdale
- Mayo Clinic in Arizona - Scottsdale
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137771
The ClinicalTrials.gov registry entry for NCT03137771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 680-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (68% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT03137771 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03137771 about?
NCT03137771 is a clinical study titled "Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer". This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride...
What is the current status of trial NCT03137771?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2017-04-07. Estimated completion is 2028-12.
What conditions does trial NCT03137771 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03137771?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Intensity-Modulated Radiation Therapy (IMRT) (RADIATION), 3-Dimensional Conformal Radiation Therapy (3D-CRT) (RADIATION), Pemetrexed Disodium (DRUG).
Who is sponsoring clinical trial NCT03137771?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03137771 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
COMPLETED · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Recurrent Non-Small Cell Lung Carcinoma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.